Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.
Particle size and shape influence virtually every aspect of mining operations – from the transport and deposition of ...
The AACE consensus statement emphasizes improvement of overall health in addition to weight reduction among adults with obesity and adiposity-based chronic disease.
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic ...
3d
X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan
Executive Chair Adam Craig said the company’s near-term focus is centered on advancing mavorixafor in chronic neutropenia, as ...
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.
Hypertension is the leading risk factor for cardiovascular disease, the most common cause of death worldwide. Less than half the people with high blood pressure are aware of their diagnosis, and only ...
Basic economy seats come with cheaper fares, but seat selection and baggage is limited and varies between airlines. Many or all of the products on this page are from partners who compensate us when ...
Each economy ticke offers different perks along with standard economy seating. Many or all of the products on this page are from partners who compensate us when you click to or take an action on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results